1. Home
  2. TG vs INBX Comparison

TG vs INBX Comparison

Compare TG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

HOLD

Current Price

$7.82

Market Cap

353.3M

Sector

Industrials

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$103.07

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TG
INBX
Founded
1988
2010
Country
United States
United States
Employees
N/A
110
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
353.3M
1.5B
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
TG
INBX
Price
$7.82
$103.07
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$150.00
AVG Volume (30 Days)
189.9K
442.3K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
151.06
N/A
EPS
0.17
N/A
Revenue
$800,821,000.00
$1,300,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$46.94
N/A
Revenue Growth
8.29
550.00
52 Week Low
$6.25
$12.80
52 Week High
$10.53
$155.29

Technical Indicators

Market Signals
Indicator
TG
INBX
Relative Strength Index (RSI) 39.71 45.50
Support Level $7.31 $99.20
Resistance Level $8.04 $153.14
Average True Range (ATR) 0.44 11.61
MACD -0.07 -3.13
Stochastic Oscillator 20.35 7.41

Price Performance

Historical Comparison
TG
INBX

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: